New xenograft-based dressing might hit the market by summer

02/21/2012 | MedCityNews.com

Harbor Medtech is preparing to submit a request that the FDA approve its NeuvoCell wound dressing based on porcine tissue. NeuvoCell will be less expensive than similar products already on the market, requires applications only once or twice instead of every seven to 10 days, and will be appropriate to treat diabetic foot ulcers, pressure ulcers and burns, founder Jerry Mezger said.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA